Katherine Fisher

Dancer

Osteoarthritis Patient

Watch Katherine's Story

Mark LaBonge

Motion Picture Steadicam
Camera Operator

Osteoarthritis Patient

Watch Mark's Story

Shawn Johannesson

Sales Representative

Osteoarthritis Patient

Read Shawn's Story

Francesco Prandoni

Director of Business Operations Doc Events

Osteoarthritis Patient

Read Francesco's Story

BREAKTHROUGH in the treatment of osteoarthritis (OA) knee pain, HYMOVIS® is helping active people everywhere write their own story about moving past pain and back to the things they love in life. If a simple, two-injection regimen for convenient and efficient OA treatment sounds good to you, take a moment to learn more – then start your own success story with HYMOVIS®.

What is OA?

OA is a common condition that causes joints to become stiff and painful. Millions of people have this condition1, so, if you have been diagnosed with it, you are not alone!

Learn More »

Treatment Options

It is important to understand there are both non-drug treatments and drug therapy for the treatment of osteoarthritis of the knee.

Learn More »

Knee Exercises

Knee exercises can be effective treatment for your knee joint pain.

Learn More »

FAQ's

Recently Asked

What should I expect from HYMOVIS® treatment?

HYMOVIS® is intended to provide relief from your osteoarthritis knee pain when simple painkillers, exercise or physical therapy have failed to give you adequate pain relief. HYMOVIS®, a new therapy recently approved by the FDA, is a thick, gel-like solution that acts like a lubricant and shock absorber in the knee joint. For many patients HYMOVIS® injections may provide up to six months of relief from osteoarthritis knee pain.2,3,4

See More FAQ's »

Contact Us

Sign-up for our Newsletter!



Important Safety Information

HYMOVIS® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics (e.g., acetaminophen).

HYMOVIS® is contraindicated in patients with known hypersensitivity (allergy) to hyaluronate preparations or gram-positive bacterial proteins. Do not administer HYMOVIS® to patients with infections or skin diseases in the area of the injection site or joint.

The safety and effectiveness of the use of HYMOVIS® have not been tested in pregnant women, nursing mothers, or children. The safety and effectiveness of the use of HYMOVIS® in joints other than the knee, or for use concomitantly with other intra-articular (IA) injections, have not been established. The effectiveness of repeat treatment cycles of HYMOVIS® has not been established.

Arthralgia, transient pain, or swelling may occur after the IA injection. The incidence of arthralgia in the clinical study for HYMOVIS® was equivalent to the control group. No serious adverse events or pseudoseptic reactions were reported. Transient increases in inflammation following any IA hyaluronan injection have been reported in some patients with inflammatory joint conditions.

Strict aseptic technique should be used by licensed medical professionals trained to deliver agents into the knee joint. Joint effusion should be removed prior to injection of HYMOVIS®. Do not use disinfectants containing quaternary ammonium salts for skin preparation as hyaluronan can precipitate in their presence.

Patients should avoid strenuous or prolonged (eg, more than one hour) physical activities within 48 hours following the IA injection.

Please see Prescribing Information.

Rx Only

HYMOVIS and HYADD 4 are registered trademarks of Fidia Farmaceutici S.p.A., Abano Terme, Italy. HYMOVIS® is manufactured by Fidia Farmaceutici S.p.A., Abano Terme, Italy. ©2017 Fidia Pharma USA Inc, Florham Park, NJ 07932